公开(公告)号：US20090253148A1

公开(公告)日：2009-10-08

申请号：US12394605

申请日：2009-02-27

申请人： David Piper ,  Stephen Hess ,  Mohammed Saleh Shekhani ,  Thomas Livelli ,  Zhong Zhong ,  Steve Duff ,  Kurt Vogel

发明人： David Piper ,  Stephen Hess ,  Mohammed Saleh Shekhani ,  Thomas Livelli ,  Zhong Zhong ,  Steve Duff ,  Kurt Vogel

IPC分类号： G01N33/53 ,  G01N33/566 ,  C12N5/06 ,  C12N5/08 ,  C07D491/10

CPC分类号： G01N33/582 ,  C07D491/107 ,  G01N33/6872 ,  Y10T436/13

摘要： Disclosed are assays, methods, and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. In particular, whether a test compound has the effect to prolong the Q-T interval as measured by an electrocardiogram in a human. The assays, methods, and kits disclosed herein make use of the binding interaction between novel fluorescent tracers and the hERG K+ channel, and the propensity of a test compound to influence that binding interaction.

摘要翻译： 公开了用于筛选测试化合物在受试者中诱导心脏毒性的能力的测定，方法和试剂盒。 特别地，测试化合物是否具有延长通过人心电图测量的Q-T间期的作用。 本文公开的测定法，方法和试剂盒利用新型荧光示踪剂和hERG K +通道之间的结合相互作用以及测试化合物影响该结合相互作用的倾向。

公开(公告)号：US20120231541A1

公开(公告)日：2012-09-13

申请号：US13417008

申请日：2012-03-09

申请人： David Piper ,  Stephen Hess ,  Mohammed Saleh Shekhani ,  Thomas Livelli ,  Zhong Zhong ,  Steve Duff ,  Kurt Vogel

发明人： David Piper ,  Stephen Hess ,  Mohammed Saleh Shekhani ,  Thomas Livelli ,  Zhong Zhong ,  Steve Duff ,  Kurt Vogel

IPC分类号： C12N5/071 ,  C12N5/10 ,  C12N5/073

CPC分类号： G01N33/582 ,  C07D491/107 ,  G01N33/6872 ,  Y10T436/13

摘要： Disclosed are assays, methods, and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. In particular, whether a test compound has the effect to prolong the Q-T interval as measured by an electrocardiogram in a human. The assays, methods, and kits disclosed herein make use of the binding interaction between novel fluorescent tracers and the hERG K+ channel, and the propensity of a test compound to influence that binding interaction.

摘要翻译： 公开了用于筛选测试化合物在受试者中诱导心脏毒性的能力的测定，方法和试剂盒。 特别地，测试化合物是否具有延长通过人心电图测量的Q-T间期的作用。 本文公开的测定法，方法和试剂盒利用新型荧光示踪剂和hERG K +通道之间的结合相互作用以及测试化合物影响该结合相互作用的倾向。

公开(公告)号：US08133695B2

公开(公告)日：2012-03-13

申请号：US12394605

申请日：2009-02-27

申请人： David Piper ,  Kurt Vogel ,  Mohammed Saleh Shekhani ,  Stephen Hess ,  Steve Duff ,  Thomas Livelli ,  Zhong Zhong

发明人： David Piper ,  Kurt Vogel ,  Mohammed Saleh Shekhani ,  Stephen Hess ,  Steve Duff ,  Thomas Livelli ,  Zhong Zhong

IPC分类号： G01N33/53 ,  G01N33/532 ,  G01N33/533

CPC分类号： G01N33/582 ,  C07D491/107 ,  G01N33/6872 ,  Y10T436/13

摘要： Disclosed are assays, methods, and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. In particular, whether a test compound has the effect to prolong the Q-T interval as measured by an electrocardiogram in a human. The assays, methods, and kits disclosed herein make use of the binding interaction between novel fluorescent tracers and the hERG K+ channel, and the propensity of a test compound to influence that binding interaction.

摘要翻译： 公开了用于筛选测试化合物在受试者中诱导心脏毒性的能力的测定，方法和试剂盒。 特别地，测试化合物是否具有延长通过人心电图测量的Q-T间期的作用。 本文公开的测定法，方法和试剂盒利用新型荧光示踪剂和hERG K +通道之间的结合相互作用以及测试化合物影响该结合相互作用的倾向。

公开(公告)号：US06664229B2

公开(公告)日：2003-12-16

申请号：US09211823

申请日：1998-12-15

申请人： James Joseph Hagan ,  Jonathan Alexander Terrett ,  Neil Upton ,  David Piper ,  Martin Ian Smith ,  Guy Anthony Kennett ,  Saraswati R. Patel

发明人： James Joseph Hagan ,  Jonathan Alexander Terrett ,  Neil Upton ,  David Piper ,  Martin Ian Smith ,  Guy Anthony Kennett ,  Saraswati R. Patel

IPC分类号： A61K3817

CPC分类号： C07K16/28 ,  A61K38/22

摘要： Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose or treat diseases relating to the under- or over-expression of HFGAN72 receptor ligands are also provided. In addition, methods of identifying agonists or antagonists of the interaction of HFGAN72 receptor ligands with the HFGAN72 receptor are provided. Methods of treatment by administering the identified agonists or antagonists to patients in need thereof are further disclosed.

摘要翻译： 提供HFGAN72受体配体的多肽和编码多肽的多核苷酸。 还提供了使用这些多肽诊断或治疗与HFGAN72受体配体的低表达或过度表达有关的疾病的方法。 另外，提供了识别HFGAN72受体配体与HFGAN72受体相互作用的激动剂或拮抗剂的方法。 还公开了通过将所鉴定的激动剂或拮抗剂给予需要的患者的治疗方法。